Comparative Pharmacology
Head-to-head clinical analysis: LINAGLIPTIN versus ONGLYZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LINAGLIPTIN versus ONGLYZA.
LINAGLIPTIN vs ONGLYZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Linagliptin is a competitive, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) levels, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) to enhance glucose-dependent insulin secretion and suppress glucagon release.
5 mg orally once daily
2.5 mg or 5 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours, allowing once-daily dosing. No accumulation at steady state.
Clinical Note
moderateLinagliptin + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Delavirdine
"The serum concentration of Delavirdine can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Clarithromycin
"The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Linagliptin."
Clinical Note
moderateLinagliptin + Ranolazine
Terminal elimination half-life is approximately 12.4 hours for saxagliptin. The half-life of its active metabolite is about 2.1 hours. The pharmacologically relevant half-life supports once-daily dosing.
Approximately 90% of absorbed dose is excreted unchanged in feces (biliary/fecal route), and about 5% is excreted unchanged in urine. Renal excretion is minimal (<1% as metabolites).
Approximately 75% of the administered dose is excreted in urine, with about 21% recovered as parent drug, and the remainder as metabolites. Fecal excretion accounts for about 22% of the dose, primarily as parent drug and metabolites.
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor
"The serum concentration of Ranolazine can be increased when it is combined with Linagliptin."